If there is going to be a takeover likely in the next 6 to 12 months it could be unnecessary and even unfair to appoint a new CEO in the short term. The company that acquires VLA would probably want to terminate them anyway.
At the stage VLA is at, the key task now and all eyes are on the Phase II study results. I think the experience of our current team and board can get the job done.
I would think VLA would only need to appoint a new CEO in the short term if there were plans to commercialise CAVATAK in-house or in partnership. But a full takeover is the most appealing and likely outcome for VLA and it's shareholders should CAVATAK show compelling efficacy.
Given that the study is open label, positive information on the study is likely to be released almost patient by patient as they reach the 6 month end-point. A clear picture of CAVATAK's efficacy could emerge well before all the patients are enrolled. A few more successes over the next couple of months could really stir up interested suitors and a race for acquisition.
I am not game to take a quick short term trading profit but good luck to those who want to chance it.
VLA Price at posting:
39.6¢ Sentiment: Hold Disclosure: Held
